Ten years ago, the U.S. Supreme Court issued its 5-3 decision in FTC v. Actavis, which held that the rule of reason should govern so-called “pay-for-delay” patent litigation settlement agreements between brand name and generic pharmaceutical manufacturers. In this episode, hosts Aaron Yeater and Alicia Downey talk to Kristen O’Shaughnessy and Dan Grossbaum about how the decision has shaped litigation in the years since and its implications for antitrust challenges in other industries. Listen to this episode to learn about the impact of the Actavis decision in the past ten years and in the future.
Kristen O’Shaughnessy, Partner, White & Case
Daniel Grossbaum, Associate, White & Case
Alicia Downey, Principal, Downey Law LLC and Aaron Yeater, Managing Principal, Analysis Group